• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基层医疗中慢性肾脏病患者的检测与管理:最新指南综述

Detecting and managing the patient with chronic kidney disease in primary care: A review of the latest guidelines.

作者信息

Mayne Kaitlin J, Hanlon Peter, Lees Jennifer S

机构信息

School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.

Glasgow Renal and Transplant Unit, NHS Greater Glasgow and Clyde, Glasgow, UK.

出版信息

Diabetes Obes Metab. 2024 Nov;26 Suppl 6:43-54. doi: 10.1111/dom.15625. Epub 2024 May 3.

DOI:10.1111/dom.15625
PMID:38699995
Abstract

Chronic kidney disease (CKD) is a major global health problem, affecting about 9.5% of the population and 850 million people worldwide. In primary care, most CKD is caused by diabetes and/or hypertension, but a substantial proportion of cases may have alternative causes. During the early stages, CKD is asymptomatic, and many people are unaware that they are living with the disease. Despite the lack of symptoms, CKD is associated with elevated risks of cardiovascular disease, progressive kidney disease, kidney failure and premature mortality. Risk reduction strategies are effective and cost-effective but require early diagnosis through testing of the estimated glomerular filtration rate and albuminuria in high-risk populations. Once diagnosed, the treatment of CKD centres around lifestyle interventions, blood pressure and glycaemic control, and preventative treatments for cardiovascular disease and kidney disease progression. Most patients with CKD should be managed with statins, renin-angiotensin-aldosterone system inhibitors and sodium-glucose cotransporter-2 inhibitors. Additional treatment options to reduce cardiorenal risk are available in patients with diabetes, including glucagon-like peptide-1 receptor agonists and non-steroidal mineralocorticoid receptor antagonists. The Kidney Failure Risk Equation is a new tool that can support the identification of patients at high risk of progressive kidney disease and kidney failure and can be used to guide referrals to nephrology. This review summarizes the latest guidance relevant to managing adults with, or at risk of, CKD and provides practical advice for managing patients with CKD in primary care.

摘要

慢性肾脏病(CKD)是一个重大的全球健康问题,影响着全球约9.5%的人口,即8.5亿人。在初级医疗保健中,大多数CKD由糖尿病和/或高血压引起,但相当一部分病例可能有其他病因。在疾病早期,CKD没有症状,许多人并未意识到自己患有这种疾病。尽管没有症状,但CKD与心血管疾病、进行性肾病、肾衰竭和过早死亡风险升高相关。风险降低策略有效且具有成本效益,但需要通过检测高危人群的估计肾小球滤过率和蛋白尿进行早期诊断。一旦确诊,CKD的治疗围绕生活方式干预、血压和血糖控制以及心血管疾病和肾病进展的预防性治疗展开。大多数CKD患者应使用他汀类药物、肾素-血管紧张素-醛固酮系统抑制剂和钠-葡萄糖协同转运蛋白2抑制剂进行管理。对于糖尿病患者,还有其他降低心肾风险的治疗选择,包括胰高血糖素样肽-1受体激动剂和非甾体类盐皮质激素受体拮抗剂。肾衰竭风险方程是一种新工具,可帮助识别有进行性肾病和肾衰竭高风险的患者,并可用于指导转诊至肾脏病科。本综述总结了与管理患有CKD或有CKD风险的成年人相关的最新指南,并为初级医疗保健中管理CKD患者提供实用建议。

相似文献

1
Detecting and managing the patient with chronic kidney disease in primary care: A review of the latest guidelines.基层医疗中慢性肾脏病患者的检测与管理:最新指南综述
Diabetes Obes Metab. 2024 Nov;26 Suppl 6:43-54. doi: 10.1111/dom.15625. Epub 2024 May 3.
2
Early Identification and Management of Chronic Kidney Disease: A Narrative Review of the Crucial Role of Primary Care Practitioners.慢性肾脏病的早期识别与管理:初级保健从业者关键作用的叙述性综述。
Adv Ther. 2024 Oct;41(10):3757-3770. doi: 10.1007/s12325-024-02957-z. Epub 2024 Aug 20.
3
Primary and Secondary Prevention of Cardiovascular Disease in Patients with Chronic Kidney Disease.慢性肾脏病患者的心血管疾病一级和二级预防。
Curr Atheroscler Rep. 2019 Jun 22;21(9):32. doi: 10.1007/s11883-019-0794-6.
4
A Population-Based Analysis of Quality Indicators in CKD.基于人群的慢性肾脏病质量指标分析。
Clin J Am Soc Nephrol. 2017 May 8;12(5):727-733. doi: 10.2215/CJN.08720816. Epub 2017 Apr 4.
5
Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis.早期转介策略在管理有肾脏疾病标志物的人群中的应用:对临床有效性、成本效益和经济分析证据的系统评价。
Health Technol Assess. 2010 Apr;14(21):1-184. doi: 10.3310/hta14210.
6
Management of chronic kidney disease in type 2 diabetes: screening, diagnosis and treatment goals, and recommendations.2 型糖尿病慢性肾脏病的管理:筛查、诊断和治疗目标以及建议。
Postgrad Med. 2022 May;134(4):376-387. doi: 10.1080/00325481.2021.2009726. Epub 2021 Dec 29.
7
SGLT2i for evidence-based cardiorenal protection in diabetic and non-diabetic chronic kidney disease: a comprehensive review by EURECA-m and ERBP working groups of ERA.SGLT2抑制剂在糖尿病和非糖尿病慢性肾脏病中基于证据的心脏肾脏保护作用:欧洲肾脏协会(ERA)的EURECA-m和ERBP工作组的综合综述
Nephrol Dial Transplant. 2023 Oct 31;38(11):2444-2455. doi: 10.1093/ndt/gfad112.
8
Barriers to early diagnosis of chronic kidney disease and use of sodium-glucose cotransporter-2 inhibitors for renal protection: A comprehensive review and call to action.慢性肾脏病早期诊断障碍和钠-葡萄糖共转运蛋白-2 抑制剂用于肾脏保护的障碍:全面综述及行动呼吁。
Diabetes Obes Metab. 2024 Oct;26(10):4165-4177. doi: 10.1111/dom.15789. Epub 2024 Aug 14.
9
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.达格列净与慢性肾脏病不良结局预防(DAPA-CKD)试验:基线特征。
Nephrol Dial Transplant. 2020 Oct 1;35(10):1700-1711. doi: 10.1093/ndt/gfaa234.
10
Diabetic kidney disease in type 2 diabetes: a consensus statement from the Swiss Societies of Diabetes and Nephrology.2型糖尿病中的糖尿病肾病:瑞士糖尿病学会和肾脏病学会的共识声明
Swiss Med Wkly. 2023 Jan 6;153:40004. doi: 10.57187/smw.2023.40004.

引用本文的文献

1
Chronic kidney disease in the primary care setting: A narrative review.基层医疗环境中的慢性肾脏病:一篇叙述性综述。
J Gen Fam Med. 2025 Jul 29;26(5):385-393. doi: 10.1002/jgf2.70054. eCollection 2025 Sep.
2
Evaluation of the Correlation between Gut Microbiota and Renal Function in Chronic Kidney Disease Patients.慢性肾脏病患者肠道微生物群与肾功能的相关性评估
J Microbiol Biotechnol. 2025 Jun 17;35:e2502039. doi: 10.4014/jmb.2502.02039.